课题基金 / 基金详情

Elucidating mechanisms for artemisinin-induced dormancy in Plasmodium falciparum

Elucidating mechanisms for artemisinin-induced dormancy in Plasmodium falciparum
阐明青蒿素诱导恶性疟原虫休眠的机制
批准号:
10742385
负责人:
DENNIS E KYLE
金额:
$22.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-16 至 2025-07-31

项目摘要

项目成果

DENNIS E KYLE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Among the numerous problems plaguing the malaria elimination efforts is the emergence and spread of drug resistance in P. falciparum. Resistance to artemisinin has led to reduced efficacy of artemisinin combination therapy (ACTs) and ultimately selection of resistance to the partner drugs (e.g., piperaquine). Clearly the threat of multi-drug resistant malaria is as important today as it has ever been, with the precious gains in malaria control threatened by the potential for the spread of P. falciparum strains that are resistant to all currently available treatment drugs. Resistance to artemisinin is not the only factor responsible for treatment failures. Even before artemisinin resistance emerged, recrudescent infections were commonly observed when patients were treated with artemisinin derivatives alone. In some studies, even 5-7 days of treatment with artesunate alone led to ~10% recrudescent infections. The underlying cause of these recrudescent infections has been attributed to the unique ability of artemisinin to arrest the growth of ring stages of P. falciparum. These dormant rings can persist for days to weeks before recovering and growing normally to cause a recrudescent infection. Our published and preliminary data led us to the hypothesis that selection of artemisinin resistance is a two-step process in which the initial responses of the parasite to artemisinin drug pressure is an enhanced dormancy phenotype that confers increased tolerance to drug; subsequently resistance conferring mutations occur (e.g., K13). In Aim 1 we will overexpress genes in a novel chromosome 10 copy number variant we identified in independently derived artemisinin-resistant clones. In Aim 2 will use novel high content imaging assays to quantify enhanced dormancy recovery phenotypes in artemisinin-resistant versus -susceptible P. falciparum. The results of these studies will provide evidence for the molecular basis of recovery from artemisinin-induced dormancy and possibly reveal new mechanisms of resistance to artemisinin.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lead optimization and target identification of drugs targeting hypnozoites
  • 批准号:
    10035076
  • 项目类别:
  • 资助金额:
    $70.22万
  • 财政年份:
    2020
  • 负责人:
    DENNIS E KYLE
  • 依托单位:
Lead optimization and target identification of drugs targeting hypnozoites
  • 批准号:
    10455026
  • 项目类别:
  • 资助金额:
    $66.16万
  • 财政年份:
    2020
  • 负责人:
    DENNIS E KYLE
  • 依托单位:
Lead optimization and target identification of drugs targeting hypnozoites
  • 批准号:
    10688200
  • 项目类别:
  • 资助金额:
    $65.67万
  • 财政年份:
    2020
  • 负责人:
    DENNIS E KYLE
  • 依托单位:
Lead optimization and target identification of drugs targeting hypnozoites
  • 批准号:
    10231087
  • 项目类别:
  • 资助金额:
    $68.03万
  • 财政年份:
    2020
  • 负责人:
    DENNIS E KYLE
  • 依托单位:
海外基金